RECOGNITION AWARDS

Fellow of the American Society of Clinical Oncology
Frances A. Shepherd, MD, Princess Margaret Cancer Centre, University Health Network, Toronto
Presented during the Opening Session, Saturday, June 3, 9:30 AM, Hall B1

International Women Who Conquer Cancer Mentorship Award
Mary Gospodarowicz, MD, FRCR, FRCPC, University of Toronto, Princess Margaret Cancer Centre

2017 Career Development Award
Scott V. Bratman, MD, PhD, Princess Margaret Cancer Centre

Novartis Oncology Young Canadian Investigator Award
Nathalie Daaboul, MD, FRCPC, Ottawa Hospital Research Institute
CCTG IND.226 - Immune-related adverse events with platinum chemotherapy with durvalumab ± tremelimumab
(Abstract #3058)
Presented Sunday, June 4, 6:30 PM

ABSTRACTS - Friday, June 2, 2017

CCTG OV.18 / MRC ICON6
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer
Session Title: Gynecologic Cancer
Date: Friday, June 2
Session Type: Oral Abstract Session
Time: 3:00 PM - 6:00 PM – Abstract presentation @ 5:00 PM
Location: S406, Abstract #5506


http://abstracts.asco.org/199/AbstView_199_191817.html
CCTG EN.7 / (DCGOG PORTEC-3)

**Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.**

- **Session Title:** Gynecologic Cancer
- **Date:** Friday, June 2
- **Session Type:** Oral Abstract Session
- **Time:** 3:00 PM - 6:00 PM – Abstract presentation @ 5:00 PM
- **Location:** S406, Abstract #5502


[http://abstracts.asco.org/199/AbstView_199_180760.html](http://abstracts.asco.org/199/AbstView_199_180760.html)

### ABSTRACTS - Saturday, June 3, 2017

**CCTG BR.26**

**Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer**

- **Session Title:** Lung Cancer – Non-Small Cell Metastatic
- **Date:** Saturday, June 3
- **Session Type:** Poster Session
- **Time:** 8:00 AM to 11:30 AM
- **Location:** Hall A, Abstract #9024; Poster Board #350

Penelope Ann Bradbury, Keyue Ding, Peter Michael Ellis, Lesley Seymour, Frank De Kievit, Greg Jones, Clive D. Morris, Emma Green, Glenwood D. Goss, Ming Sound Tsao, Frances A. Shepherd

[http://abstracts.asco.org/199/AbstView_199_193212.html](http://abstracts.asco.org/199/AbstView_199_193212.html)

**Cetuximab clearance and survival in patients with metastatic colorectal cancer**

- **Session Title:** Gastrointestinal (Colorectal) Cancer
- **Date:** Saturday, June 3
- **Session Type:** Poster Session
- **Time:** 8:00 AM to 11:30 AM
- **Location:** Hall A, Abstract #3600; Poster Board #223

Di Maria Jiang, Hao-Wen Sim, Lillian L. Siu, Jeremy David Shapiro, Geoffrey Liu, Timothy Jay Price, Derek J. Jonker, Christos Stelios Karapetis, Andrew Strickland, Wenjiang Zhang, Mark Jeffery, Dongsheng Tu, Siobhan Ng, Sabe S. Sabesan, Jenny Shannon, Amanda Rose Townsend, Eric Morgen, Wei Xu, Christopher J. O'Callaghan, Eric Xueyu Chen

[http://abstracts.asco.org/199/AbstView_199_191202.html](http://abstracts.asco.org/199/AbstView_199_191202.html)
### CCTG CO.17/CO.20

**Age as a predictive and prognostic factor for targeted therapy treatment in metastatic chemorefractory colorectal cancer: An analysis of NCIC CTG CO.17 and CO.20.**

**Session Title:** Gastrointestinal (Colorectal) Cancer  
**Date:** Saturday, June 3  
**Session Type:** Poster Session  
**Time:** 8:00 AM to 11:30 AM  
**Location:** Hall A, Abstract #3555; Poster Board #178

Connor Wells, Lillian L. Siu, Jeremy David Shapiro, Dongsheng Tu, Derek J. Jonker, Christos Stelios Karapetis, John Simes, Geoffrey Liu, Timothy Jay Price, Niall C. Tebbutt, Christopher J. O'Callaghan

[http://abstracts.asco.org/199/AbstView_199_182256.html](http://abstracts.asco.org/199/AbstView_199_182256.html)

### CCTG CO.26

**A phase II randomized study of durvalumab plus tremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma refractory to standard therapies**

**Session Title:** Gastrointestinal (Colorectal) Cancer  
**Date:** Saturday, June 3  
**Session Type:** Poster Session  
**Time:** 8:00 AM - 11:30 AM  
**Location:** Hall A, Abstract #TPS3621; Poster Board #242b

Eric Xueyu Chen, Derek J. Jonker, Hagen F. Kennecke, Sheryl L. Koski, Alice Chia-chi Wei, Nadine M Magoski, Dongsheng Tu, Christopher J. O'Callaghan

[http://abstracts.asco.org/199/AbstView_199_189699.html](http://abstracts.asco.org/199/AbstView_199_189699.html)

### CCTG GA.3 / AGO315OG

**Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer - An international study organized by the Australasian Gastrointestinal Trials Group**

**Session Title:** Gastrointestinal (Noncolorectal) Cancer  
**Date:** Saturday, June 3  
**Session Type:** Poster Session  
**Time:** 8:00 AM to 11:30 AM  
**Location:** Hall A, Abstract #TPS4136; Poster Board #125b

Katrin Marie Sjoquist, Nick Pavlakis, Andrew James Martin, Eric Tsobanis, Sonia Yip, Yung-Jue Bang, Thierry Alcindor, Christopher J. O'Callaghan, Kohei Shitara, Tanios S. Bekaii-Saab, Axel Grothey, Li-Tzong Chen, John Simes, John Raymond Zalcberg, David Goldstein

[http://abstracts.asco.org/199/AbstView_199_188701.html](http://abstracts.asco.org/199/AbstView_199_188701.html)
CCTG CRC.2 / NCCTG N0147 (Alliance)

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX +/- cetuximab chemotherapy

Session Title: Gastrointestinal (Colorectal) Cancer
Date: Saturday, June 3
Session Type: Poster Session
Time: 8:00 AM - 11:30 AM
Location: Hall A, Abstract #3516; Poster Board #139

Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Richard M. Goldberg, Erica N Heying, Steven J. Cohen, Sharlene Gill, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Daniel J. Sargent, Balkrishna N. Jahagirdar, Michael N. Pollak, Steven R. Alberts

http://abstracts.asco.org/199/AbstView_199_193534.html

Association of immune markers and Immunoscore with survival of stage III colon carcinoma patients treated with adjuvant FOLFOX

Session Title: Gastrointestinal (Colorectal) Cancer
Date: Saturday, June 3
Session Type: Poster Session
Time: 8:00 AM - 11:30 AM
Location: Hall A, Abstract #3579; Poster Board #202

Frank A. Sinicrope, Qian Shi, Fabienne Hermitte, Erica N Heying, Al Bowen Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Daniel J. Sargent, Jerome Galon, Steven R. Alberts

http://abstracts.asco.org/199/AbstView_199_192729.html

Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX +/- cetuximab

Session Title: Gastrointestinal (Colorectal) Cancer
Date: Saturday, June 3
Session Type: Poster Session
Time: 8:00 AM - 11:30 AM
Location: Hall A, Abstract #3604; Poster Board #227

Polly A. Newcomb, Wei Sun, Xinwei Hua, Barbara L. Banbury, Amanda I. Phipps, Jonathan Kocarnik, Tabitha A. Harrison, Qian Shi, Frank A. Sinicrope, Stephen N. Thibodeau, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh Nair, Anthony Frank Shields, Balkrishna N. Jahagirdar, Ulrike Peters, Steven R. Alberts, Andrew T. Chan

http://abstracts.asco.org/199/AbstView_199_193045.html
CCTG PA.7

*A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma*

**Session Title:** Gastrointestinal (Noncolorectal) Cancer  
**Date:** Saturday, June 3  
**Session Type:** Poster Session  
**Time:** 8:00 AM - 11:30 AM  
**Location:** Hall A, Abstract #TPS4149; Poster Board #132a

Daniel John Renouf, Petr Kavan, Neesha C. Dhani, Derek J. Jonker, Alice Chia-chi Wei, Tina Hsu, Patricia A. Tang, Barbara Graham, Dongsheng Tu, Christopher J. O'Callaghan

http://abstracts.asco.org/199/AbstView_199_189427.html

---

**Accrual of older adults to Canadian Cancer Trials Group-led trials: A retrospective analysis from 1990 to 2015**

**Session Title:** Patient and Survivor Care  
**Date:** Saturday, June 3  
**Session Type:** Poster Session  
**Time:** 1:15 PM - 4:45 PM  
**Location:** Hall A, Abstract #10031; Poster Board #20

Catalina Hernandez Torres, Winson Y. Cheung, Christopher J. O'Callaghan, Tina Hsu

http://abstracts.asco.org/199/AbstView_199_183074.html

---

CCTG SC.24

*A randomized phase II/III study comparing stereotactic body radiotherapy versus conventional palliative radiotherapy for patients with spinal metastases*

**Session Title:** Patient and Survivor Care  
**Date:** Saturday, June 3  
**Session Type:** Poster Session  
**Time:** 1:15 PM to 4:45 PM  
**Location:** Hall A, Abstract #TPS10129; Poster Board #115b

Arjun Sahgal, Sten Myrehaug, Kristopher Dennis, Mitchell Liu, Edward Chow, Rebecca Wong, James B. Butler, Jeffrey Noah Greenspoon, Michael G Fehlings, Pejman Maralani, Laura Masucci, Young Lee, Michael Donald Brundage, Stanley K. Liu, Keyue Ding, Maaike Hum, Wendy R. Parulekar

http://abstracts.asco.org/199/AbstView_199_193658.html
**CCTG CL.3 / CALGB 10404 (Alliance)**

*A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)*

**Session Title:** Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia  
**Date:** Saturday, June 3  
**Session Type:** Oral Abstract Session - Abstract presentation @ 4:00 PM  
**Time:** 3:00 PM - 6:00 PM  
**Location:** S100bc, Abstract #7503


[http://abstracts.asco.org/199/AbstView_199_192498.html](http://abstracts.asco.org/199/AbstView_199_192498.html)

**ABSTRACTS - Sunday, June 4, 2017**

**CCTG MEC.3/E1609**

*A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: Preliminary safety and efficacy of the ipilimumab arms*

**Session Title:** Melanoma/Skin Cancers  
**Date:** Sunday, June 4  
**Session Type:** Oral Abstract Session - Abstract presentation @ 8:00 AM  
**Time:** 8:00 AM to 11:00 AM  
**Location:** Arie Crown Theater, Abstract #9500

Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi, Uma N. M. Rao, Gary I Cohen, Omid Hamid, Laura Fulper Hutchins, Jeffrey Alan Sosman, Harriet M. Kluger, Vernon K. Sondak, Henry B. Koon, Donald P. Lawrence, Kari Lynn Kendra, David R. Minor, Carrie B. Lee, Mark R Albertini, Lawrence E. Flaherty, Teresa M. Petrella, John M. Kirkwood

[http://abstracts.asco.org/199/AbstView_199_189552.html](http://abstracts.asco.org/199/AbstView_199_189552.html)
CCTG MAC.11/S0221

**SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy.**

**Session Title:** Breast Cancer—Local/Regional/Adjuvant  
**Date:** Sunday, June 4  
**Session Type:** Poster Session (Board #121)  
**Time:** 8:00 AM to 11:30 AM  
**Location:** Hall A - Abstract #521


[http://abstracts.asco.org/199/AbstView_199_184069.html](http://abstracts.asco.org/199/AbstView_199_184069.html)

**ABSTRACTS - Monday, June 5, 2017**

CCTG IND.226

**Immune-related adverse events with platinum chemotherapy with durvalumab ± tremelimumab**

**Session Title:** Developmental Therapeutics – Immunotherapy  
**Date:** Monday, June 5  
**Session Type:** Poster Session  
**Time:** 8:00 AM to 11:30 AM  
**Location:** Hall A, Abstract #3058; Poster Board #153

Nathalie Daaboul, Isabelle Gauthier, Dongsheng Tu, Pamela Brown-Walker, Xiaoqun Sun, Desiree Hao, Rosalyn A. Juergens, Penelope Ann Bradbury, Mihaela Mates, Mustapha Ali Tehfe, Christian K. Kollmannsberger, Peter Michael Ellis, Andrew George Robinson, Paul Wheatley-Price, Scott Andrew Laurie, Lesley Seymour

[http://abstracts.asco.org/199/AbstView_199_184113.html](http://abstracts.asco.org/199/AbstView_199_184113.html)
Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents: Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database

Session Title: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Date: Monday, June 5
Session Type: Poster Session
Time: 8:00 AM to 11:30 AM
Location: Hall A; Abstract #2534; Poster Board #26

Saskia Litière, Gaëlle Isaac, Elisabeth De Vries, Jan Bogaerts, Alice P. Chen, Janet Dancey, Robert Ford, Steve J Gwyther, Otto S. Hoekstra, Erich Huang, Nancy U Lin, Yan Liu, Sumithra J. Mandrekar, Lawrence HOWARD Schwartz, Lalitha Shankar, Patrick Therasse, Lesley Seymour

http://abstracts.asco.org/199/AbstView_199_185660.html

CCTG HN.6
Resource utilization in patients with head and neck cancer: Analysis of CCTG HN.6 (NCT00820248)

Session Title: Head and Neck Cancer
Date: Monday, June 5
Session Type: Poster Session
Time: 1:15 PM to 4:45 PM
Location: Hall A, Abstract #6067; Poster Board #55


http://abstracts.asco.org/199/AbstView_199_193331.html

CCTG IND.209
A randomized phase II study of pelareorep plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer

Session Title: Genitourinary (Prostate) Cancer
Date: Monday, June 5
Session Type: Poster Session
Time: 1:15 PM to 4:45 PM
Location: Hall A; Abstract #5021; Poster Board #95

Bernhard J. Eigl, Eric Winquist, Dongsheng Tu, Sebastien J. Hotte, Christina M. Canil, Richard William Gregg, Muhammad Zulfiqar, Scott A. North, Susan Ellard, Joseph D. Ruether, Lyly H. Le, Ankineedu Saranya Kakumanu, Ashley Theis, Christopher M. Booth, Kylea R. Potvin, Kim N. Chi, Lesley Seymour

http://abstracts.asco.org/199/AbstView_199_181391.html
CCTG MAC.13 / BIG 2-06 / NCCTG (Alliance) N063D

**Updated results from the phase III ALTTO trial comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer**

**Session Title:** Breast Cancer – Local/Regional/Adjuvant  
**Date:** Monday, June 5  
**Session Type:** Oral Abstract Session – Abstract presentation @ 10:09 AM  
**Time:** 9:45 AM to 12:45 PM  
**Location:** Hall D2; Abstract #502


[Link](http://abstracts.asco.org/199/AbstView_199_191859.html)

---

CCTG MA.34 / BIG 4-11

**APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer**

**Session Title:** Breast Cancer – Local/Regional/Adjuvant  
**Date:** Monday, June 5  
**Session Type:** Oral Abstract Session – Abstract presentation @ 9:45 AM  
**Time:** 9:45 AM to 12:45 PM  
**Location:** Hall D2; Abstract #LBA500


[Link](http://abstracts.asco.org/199/AbstView_199_189357.html)
CCTG IND.214
Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.

Category: Developmental Therapeutics – Immunotherapy
Abstract #: e14637

Derek J. Jonker, Sebastien J. Hotte, Albiruni Ryan Abdul Razak, Daniel John Renouf, Brian Lichty, John C. Bell, Jean Powers, Caroline J Breitbach, David F Stojdl, Kyle B Stephenson, Jonathan L Bramson, Jeff Hummel, Chantal G Lemay, Jean-Claude Cutz, Julie Wells, Robin Eady, Xiaoqun Sun, Dongsheng Tu, Janet Dancey

http://abstracts.asco.org/199/AbstView_199_188323.html

* Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2017 ASCO Annual Meeting but not presented at the Meeting, can be found online only.